

# Leading Factor Driving Urinary Retention Drug Market in 2025: Surging Prevalence Rates Fuel Urinary Incontinence

*The Business Research Company's  
Urinary Retention Drug Global Market  
Report 2025 – Market Size, Trends, And  
Global Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED  
KINGDOM, May 29, 2025

/EINPresswire.com/ -- The prominence  
of the urinary retention drug market

has been on the rise globally. Aided primarily by aging demographics, significant healthcare investments, and jumps in medical infrastructure, the market size recorded a robust growth from \$3.87 billion in 2024 to an estimated \$4.11 billion in 2025. This compound annual growth rate CAGR of 6.4% was also fueled by the increasing prevalence of benign prostatic hyperplasia BPH worldwide.



The Business Research  
Company's Latest Report  
Explores Market Driver,  
Trends, Regional Insights -  
Market Sizing & Forecasts  
Through 2034"

*The Business Research  
Company*

What Lies Ahead For The Future Urinary Retention Drug  
Market?

Going forward, the urinary retention drug market foresees sustained momentum in growth. The market size is expected to burgeon to \$5.21 billion in 2029, reflecting a compound annual growth rate CAGR of 6.1%. This growth is spurred by the increasing prevalence of urinary retention, exacerbated by rising instances of postoperative urinary retention and urinary incontinence UI. Further

contributing to the growth is the heightened awareness about the benefits of early diagnosis and subsequent treatment of these conditions along with the increasing prevalence of benign prostatic hyperplasia.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=23552&type=smp>

What Are The Fundamental Drivers Powering [The Urinary Retention Drug Market?](#)

The Business  
Research Company

Urinary Retention Drug Global Market Report 2025



The increasing prevalence of urinary disorders is undeniably a key factor bolstering the growth of the urinary retention drug market. These disorders affect the urinary system, manifesting issues such as difficulty urinating, pain, incontinence, or retention. A prime contributor to this trend is the increasing incidence of diabetes where high blood sugar levels can inflict damage to the kidneys and urinary tract. This can lead to conditions like diabetic nephropathy and multiple urinary tract infections.

In response, urinary retention drugs improve urine flow, relax bladder muscles, and relieve symptoms such as difficulty urinating. By doing so, they enhance comfort and bladder function. To illustrate, as of October 2023, the National Health Service NHS England reported a staggering 147,285 hospital admissions for the 2022/23 period, with the primary diagnosis being urinary tract infection UTI. A majority of these cases, approximately 56% totaling 82,392 admissions, were individuals aged over 65. The highest number of admissions occurred in the 80-84 age group, with 17,280 cases. This escalating prevalence thus serves as a significant propeller for the urinary retention drug market.

Which Are The Key Industry Players In The Urinary Retention Drug Market?

Key industry players in the urinary retention drug market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Medtronic plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Lupin Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Ajanta Pharma Limited, Ferring Pharmaceuticals Inc., UroGen Pharma Ltd.

What Are The Current [Urinary Retention Drug Market Trends?](#)

The market is witnessing a focus on the development of novel formulations such as extended-release tablets. These innovative medications ensure patient compliance and offer extended symptom relief. Essentially, extended-release tablets gradually release the active ingredient over an extended period, maintaining a steady drug concentration in the bloodstream. This control mechanism reduces dosing frequency compared to immediate-release tablets. In a significant development, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched a generic version of Mirabegron for overactive bladder OAB in April 2024. This medication is administered as a once-daily oral dosage.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/urinary-retention-drug-global-market-report>

How Is The Urinary Retention Drug Market Segmented?

The urinary retention drug market report segments the market into four main categories:

1 Drug Class: Alpha Blockers, Beta-3 Agonists, Anticholinergics, Surgical Agents

2 Indication: Chronic Urinary Retention, Postoperative Urinary Retention, Neurogenic Bladder

3 Administration: Oral, Injectable, Transdermal

4 End Users: Hospitals, Homecare, Specialty Clinics, Other End Users.

It further categorizes these segments into subsegments as follows:

1 Alpha Blockers: Alpha-1 Blockers, Alpha-2 Blockers

2 Beta-3 Agonists: Selective Beta-3 Agonists

3 Anticholinergics: Antimuscarinics, Non-Selective Anticholinergics

4 Surgical Agents: Anesthetics, Hemostatic Agents, Muscle Relaxants, Antibiotic Prophylaxis.

What Is The Regional Insight Into The Urinary Retention Drug Market?

Following this, the report proceeds to analyze the regional coverage of the urinary retention drug market. North America represents the most significant market regionality as of 2024. However, the report also covers other geographies including Asia-Pacific, Western Europe, Eastern Europe, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Urinary Tract Cancer Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/urinary-tract-cancer-global-market-report>

Urinary Stone Treatment Devices And Equipment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/urinary-stone-treatment-devices-and-equipment-global-market-report>

Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/urinary-incontinence-and-pelvic-organ-prolapse-devices-and-equipment-global-market-report>

[About The Business Research Company](#)

Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [info@tbrc.info](mailto:info@tbrc.info)

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: [https://www.youtube.com/channel/UC24\\_f10rV8cR5DxICpgmyFQ](https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ)

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/817126531>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.